Loading...
Market
What will be Roche's strategic focus post-Poseida acquisition by 2025?
2
Resolution / Starting Odds
Focus on cancer treatments • 25%
Focus on genetic engineering • 25%
Focus on both equally • 25%
Focus on other areas • 25%
Roche's strategic announcements and press releases
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
CFO • 25%
None • 25%
CTO • 25%
CEO • 25%
Investment in new vaccine technology • 25%
No significant strategic move • 25%
New partnership in vaccine development • 25%
Expansion of vaccine production • 25%
Other • 25%
Infectious diseases • 25%
Neurological disorders • 25%
Cancer • 25%
Pursue mergers or acquisitions • 25%
Develop a new obesity drug • 25%
Focus on improving CagriSema • 25%
Increase investment in marketing existing drugs • 25%
Submit for regulatory approval • 25%
Seek further trials • 25%
Partner with another company • 25%
Discontinue development • 25%
Yes • 50%
No • 50%
Other • 25%
Roche • 25%
Pfizer • 25%
Novartis • 25%
Seek acquisition • 25%
Discontinue • 25%
Find new partner • 25%
Self-commercialize • 25%
Increase by 20% to 30% • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Increase by more than 30% • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Other • 25%
Roche • 25%
Other • 25%
GlaxoSmithKline • 25%
AstraZeneca • 25%
Pfizer • 25%